Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2014 · 10-Q
Revenue$3.86M$3.86M+42.5% vs Q2 2013 Net Income-$1.65M-$1.65MN/M vs Q2 2013 EPS Diluted-$0.05-$0.05N/M vs Q2 2013 Gross Profit$1,398,766+45.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$543,369N/M Free Cash Flowderived-$552,116N/M Margins · derivedGross margin36.3%+0.8 pt vs Q2 2013
Operating margin-42.6%−5.1 pt vs Q2 2013
Net margin-42.9%−5.2 pt vs Q2 2013
ended Jun 28, 2014 · filed Aug 12, 2014 · 45 d after period end